Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : R. Lanzillo • G. Orefice • A. Prinster • G. Ventrella • R. Liuzzi • V. Scarano • C. Florio • G. Vacca • A. Brunetti • B. Alfano • V. Brescia Morra •
- چاپ و سال / کشور: 2011
Description
The identification of predictive factors of NAbs development might have a relevant impact on clinical practice. Our objective is to look after predictive factors of NAbs development in MS IFN Beta-1b-treated patients. Database was screened for patients on IFN Beta-1b treatment with an Expanded Disability Status Scale (EDSS) at a baseline between 1 and 3.5, disease duration shorter than 15 years, and NAbs analysis performed every 6 months. The NAbs positive status was analysed in relation to baseline clinical, neuropsychological and brain imaging measures. Forty-nine patients were included. Sixteen patients had become NAbs positive at some point on IFN therapy (35%). NAbs producers differed from not producers for higher incidence of cognitive deficit and higher lesion load (OR = 5.0 and 5.6, respectively). Our study suggests that NAbs development might be a marker of a more aggressive disease and that worse outcome in NAbs producers might be biased by baseline condition.
Neurol Sci (2011) 32:287–292 DOI 10.1007/s10072-011-0483-x Received: 12 July 2010 / Accepted: 18 January 2011 / Published online: 10 February 2011
